Retension Pharmaceuticals Announces Pricing of Initial Public Offering
Net proceeds and existing cash are intended to fund completion of RTN-001’s Phase 2b trial and work toward a planned Phase 3 trial.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Retension Pharmaceuticals (RTSN) priced its upsized initial public offering at $12.00 per share, with all shares offered by the company.
The offering comprises 3,750,000 common shares and is expected to generate $45.0 million in gross proceeds before underwriting discounts, commissions and other offering expenses. Underwriters have a 30-day option to buy up to 562,500 additional shares. Trading on the Nasdaq Capital Market is expected to begin October 9, 2026, with closing expected on or about October 13, 2026. Retension intends to use net proceeds and existing cash to complete RTN-001’s Phase 2b trial in uncontrolled hypertension and prepare for, support and advance its planned Phase 3 trial.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Upsized IPO is expected to raise $45.0 million in gross proceeds before offering expenses.
- Minor point. Forward-looking: it has not happened yet and may not happen.Retension plans to fund Phase 2b completion and planned Phase 3 development with net proceeds and existing cash.
- Minor pointRTN-001 achieved placebo-adjusted systolic and diastolic blood pressure reductions in two Phase 2 pilot trials.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Issuance of 3,750,000 common shares at $12.00 each dilutes existing holders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Underwriters’ 30-day option for up to 562,500 additional shares could add dilution at the IPO price, less underwriting discounts and commissions.
- Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting discounts, commissions and other offering expenses will reduce proceeds available to Retension.
News Explained
The IPO is priced but not closed; if it closes as expected, Retension will issue all 3,750,000 shares itself, increasing the share count and reducing existing holders’ percentage ownership absent offsetting changes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of
Retension intends to use the net proceeds from the offering, together with existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension (uHTN) and to prepare for, support and advance the planned Phase 3 clinical trial of RTN-001 in uHTN, with the remainder to be used for general corporate purposes and other operating expenses.
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Titan Partners is acting as lead manager for the offering.
Registration statements relating to these securities became effective on October 8, 2026. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105 or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimsecurities.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Retension Pharmaceuticals
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.
About RTN-001
Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries not adequately reached by first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials totaling 265 enrolled subjects. In two Phase 2 pilot trials, RTN-001 has achieved clinically meaningful placebo-adjusted reductions in systolic blood pressure and diastolic blood pressure in patients with hypertension. A Phase 2b trial of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A.
Special Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to the Company’s closing of its initial public offering. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. All statements other than statements of historical fact, including statements regarding Retension’s initial public offering, future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on Retension’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, therefore you should not place undue reliance on these forward-looking statements. Words, including but not limited to, “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Retension’s actual results may differ materially from those expressed in, or implied by, such forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) on September 18, 2026 as well as other documents that may be filed by the Company from time to time with the SEC. Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC’s website at www.sec.gov. Retension undertakes no obligation to update any forward-looking statements after the date of this press release or to conform such statements to actual results or revised expectations, except as required by law.
Contact:
Press and Investor Contact
Alex Schwartz
Chief Financial Officer
investors@retensionpharmaceuticals.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Retension Pharmaceuticals’ IPO price and expected closing date?
Retension priced 3,750,000 common shares at $12.00 per share, with closing expected on or about October 13, 2026, subject to customary closing conditions. Gross proceeds are expected to be $45.0 million before underwriting discounts, commissions and other offering expenses.
What clinical testing has Retension’s RTN-001 undergone?
RTN-001 has been studied in multiple clinical trials totaling 265 enrolled subjects. Two Phase 2 pilot trials showed placebo-adjusted reductions in systolic and diastolic blood pressure in patients with hypertension, which Retension characterized as clinically meaningful. A Phase 2b trial in hypertension is ongoing.